1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This R03 grant supports pilot projects that investigate understudied proteins associated with rare diseases.
Leukodystrophies are rare diseases, and research into the proteins involved in their pathogenesis would be highly relevant.
Get alerted about grants like this
Get emailed when new opportunities from “National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Academic and research institutions are typically eligible for NIH R03 grants. This program supports early-stage research. Confirm the full requirements in the official notice before applying.
The published deadline was June 16, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) is funded by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Notice of NCATS Participation in Notice of Funding Opportunity (NOFO) PA-25-304 NIH Exploratory/Developmental Research Project Grant (Parent R21 Clini... is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This notice indicates NCATS's participation in the NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) program, highlighting areas of interest for translational science research within this mechanism.
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This parent R03 funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. NCATS's participation emphasizes its interest in supporting foundational or pilot translational research.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article